Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.
Upfront treatment with medications that target the underlying pathophysiology of prediabetes may slow patients’ progression to type 2 diabetes, report researchers.
Advisory Board member Theresa Smyth tackles an emergency case involving a type 2 diabetes patient on a new diet and treated with empagliflozin. What went wrong and how should he be managed? [Read more].
Research shows that starting second-line sulfonylurea treatment is associated with an increased risk for cardiovascular and hypoglycemic events among patients with type 2 diabetes in clinical practice, although the risk is less if they continue using metformin rather than switching completely.
This meta-analysis of observational studies assesses the association between risk of bladder cancer and exposure to pioglitazone among subjects with type 2 diabetes [read more]. Mehtälä J et al. Diabetol Int 2018. doi: 10.1007/s13340-018-0360-4
This review will evaluate mechanisms responsible for chronic kidney disease-induced insulin resistance and therapies currently available [read more]. Dave N, Wu J, Thomas S. Curr Diab Rep 2018; 18: 44. doi: 10.1007/s11892-018-1010-8
The RISE trial investigators have found that increased insulin resistance and hyperresponsive beta cells may explain the rapid progression of type 2 diabetes in children.
We present one successful case that demonstrates a significantly beneficial effect of physical exercise and lifestyle intervention in the management of type 2 diabetes mellitus [read more]. Deng Z et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0448-7
Upfront combination therapy with vildagliptin and metformin is more durable than metformin alone, and appears to have a legacy effect, report the VERIFY investigators.
Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.
Second-line therapy choices for people with type 2 diabetes vary widely throughout the world and are influenced not only by clinical characteristics but also non-medical factors such as affordability and availability, results from the DISCOVER study show.
This collection provides an overview of the epidemiology, underlying pathophysiological mechanisms, screening, assessment and management of heart failure in patients with diabetes mellitus.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
